## **CLAIMS**

## What is claimed is:

5

15

- 1. A method comprising topically administering a composition comprising a cyclodextrin and a therapeutically active agent, or a pharmaceutically acceptable salt or a prodrug thereof, to the eye of a mammal in need thereof, wherein said method is effective in improving delivery of said therapeutically active agent to the back of the eye.
  - 2. The method of claim 1 wherein said mammal is a human.
- 10 3. The method of claim 1 wherein said therapeutically active agent, or salt or prodrug thereof, is water-insoluble.
  - 4. The method of claim 1 wherein said therapeutically active agent, or salt or prodrug thereof, is water-soluble.
  - 5. The method of claim 1 wherein said therapeutically active agent is not administered to reduce intraocular pressure.
    - 6. The method of claim 1 wherein said therapeutically active agent is not administered to treat allergic conjunctivitis.
    - 7. The method of claim 1 wherein said therapeutically active agent is not administered to treat dry eye.
- 20 8. The method of claim 1 wherein said therapeutically active agent is not administered to treat a condition affecting the front of the eye.
  - 9. The method of claim 1 comprising a  $\beta$ -cyclodextrin derivative.
  - 10. The method of claim 1 comprising a  $\beta$ -cyclodextrin derivative and a water-soluble polymer.
- 25 11. The method of claim 1 comprising prednisolone acetate, hydroxypropyl-β-cyclodextrin, and hydroxypropylmethylcellulose.
  - 12. The method of claim 1 comprising a  $\gamma$ -cyclodextrin derivative.
  - 13. The method of claim 5 comprising prednisolone acetate.
  - 14. The method of claim 5 wherein said cyclodextrin derivate is
- 30 hydroxypropyl-y-cyclodextrin.
  - 15. The method of claim 5 which further comprises a cellulose derivative.

- 16. The method of claim 5 which further comprises hydroxypropylmethylcellulose having a concentration less than 1%.
- 17. The method of claim 5 comprising from 0.05% to 0.4% hydroxypropylmethylcellulose.
- 5 18. The method of claim 5 comprising about from 0.1% to 0.25% hydroxypropylmethylcellulose.
- - a container suitable for dispensing drops of said solution to the eye of a mammal in need of treatment by said prodrug, and a package which indicates that said product is useful for treatment of a disease or condition affecting the back of the eye.
- 15 20. A composition comprising a therapeutically active agent and a cyclodextrin, wherein said therapeutically active agent is intended for treatment or prevention of a disease or condition affecting the back of the eye, and wherein said composition is suitable for topical ophthalmic administration.
  - 21. The composition of claim 19 wherein said therapeutically active agent is not intended to reduce intraocular pressure.
    - 22. The method of claim 19 wherein said therapeutically active agent is not intended to treat a condition affecting the front of the eye.
    - 23. The composition of claim 20 comprising from 0.1% to 2% prednisolone acetate and from 1% to 30% of the cyclodextrin.
- 25 24. The composition of claim 23 comprising a  $\beta$ -cyclodextrin derivative.
  - 25. The composition of claim 23 comprising a  $\gamma$ -cyclodextrin derivative.

20